Drugs / TSC-201-B0702
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | solid adenocarcinoma with mucin production | — | “Filed INDs in December 2023 for TSC-201-B0702 targeting melanoma-associated antigen C2 (MAGE-C2) on HLA type B*07:02” tscan.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05973487 | May 2024 → Dec 2026 expected | adenosquamous carcinoma, anal squamous cell carcinoma, anogenital human papillomavirus infection, endocervical adenocarcinoma +8 | TScan Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | TScan Therapeutics, Inc. | Regulatory TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update tscan.com ↗
Announced the clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 targeting MAGE-C2 on HLA-B*07:02 and TSC-204-A0101 targeting MAGE-A1 on HLA-A*01:01 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | TScan Therapeutics, Inc. | TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update tscan.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSC-201-B0702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05973487 ↗ |
| Target | MAGE-C2 | “TSC-201-B0702 targeting MAGE-C2 on HLA-B\*07:02” NCT05973487 ↗ |